Made a call to ANP Investor Relations to ask a couple of questions..thought to give the responses to add to discussion. (**Remember some of us are not Chemistry Phd's so if I have made an error be gentle)
Q: With this share issue, given the companies development and operational costs, how long will this cash see the company through till? A: 2014
Q: What is the timeline for the ATL1102 development with the Chinese? A: Probably looking at signing an agreement June/July.
Q: So the start of any further testing or development of ATL1102 by the Chinese J/V would be? A: About the end of the year.
Q: The inclusion of ATL1103 increased the uptake in **Somasert for patients. What further discussions has the company had for commercialization with that supplier, are there any timelines for that as a project? A: None at the moment...(They was searching a bit here but non-committal so that's how I have to report it)
When discussing the offer they confirmed Options were not being issued to Tranch2 holders.
What I couldn't get from them was their policy on share allocation if the SPP is oversubscribed on the retail side (expected).
Interesting that the timing of the Chinese JV agreement seems to be when the options are expiring? Maybe.
It will be interesting to see who the new insto's are that got onboard with Tranche 1 IMO.
The major shareholders are really in control here because they have the ability to block Tranche 2 to limit the capital base of the company if they want. Which they may do to limit dilution of their investment.
Given that funding will take them through the next couple of years IMO the Tranche 2 offering is not necessary but would be nice to secure the funding now.
Will this second issue happen? Thats what I wonder. I guess the vote at the end of April will be interesting.
ANP Price at posting:
20.0¢ Sentiment: None Disclosure: Held
